Fig. 3.

The aromatase inhibitor letrozole prevents induction of E2 levels but does not affect cell cycle progression or expression of SRD5A1 and MUP1 in response to cyclin D1. Mice were treated (Treat.) with letrozole as outlined in experimental procedures and transfected with the cyclin D1 or control adenoviruses as in Fig. 1. A: serum E2 levels. B: hepatocyte DNA synthesis as assessed by BrdU uptake. C: Western blot of cyclin D1 and cdk1. D: RT-PCR for SRD5A1 and MUP1.